Abstract: Objective To study the value and significance of oxitinib combined with radiotherapy in the treatment of brain metastasis of NSCLC.
Methods Eighty patients with brain metastasis from non-small cell lung cancer were selected as the study object. The computer software was used to divide the patients into two groups. 40 patients who only received craniocerebral radiation therapy were set as the control group, and 40 patients who received combination of oxitinib and craniocerebral radiation therapy were set as the experimental group. The clinical efficacy, intracranial and extracranial progression free survival period, the expression level of antigen, carcinoembryonic antigen(CEA) and vascular endothelium growth factor(VEGF) were compared between two groups.
Results The clinical effect of the experimental group was better than that of the control group, the objective remission rate and disease control rate were higher than that of the control group, and the intracranial and extracranial progression free survival period was longer than that of the control group(P＜0.05 or P＜0.01). After treatment, the expression level of CEA and VEGF between two groups was significantly lower than that before treatment, and the expression level of CEA and VEGF in the experimental group was significantly lower than that in the control group(P＜0.01).
Conclusion The treatment of brain metastasis of NSCLC with oxitinib combined with craniocerebral radiotherapy can improve the clinical efficiency, reduce the expression level of CEA and VEGF, and prolong the survival period of patients. The effect is significant, which is worthy of clinical use.

Key words: carcinoma, non-small-cell lung； neoplasm metastasis； oxytinib, cranial irradiation